Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, Zhao H, Chen R, Zu C, Gu T, Xiao P, Hong R, Feng J, Fu S, Kong D, Xu H, Cui J, Huang S, Liang B, Yuan X, Cui Q, Guo H, Yu Y, Feng Y, Jin C, Ren J, Chang AH, Wang D, Huang H. Hu Y, et al. Among authors: chang ah. N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812. N Engl J Med. 2024. PMID: 38657244
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.
Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, Wu W, Zhao K, Xiao L, Zhang Y, Wu Z, Xu H, Chang AH, Huang H. Hu Y, et al. Among authors: chang ah. Bone Marrow Transplant. 2019 Aug;54(8):1208-1217. doi: 10.1038/s41409-018-0403-2. Epub 2018 Dec 5. Bone Marrow Transplant. 2019. PMID: 30518980
Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z, Xiao L, Chang AH, Huang H, Zhao K. Wang J, et al. Among authors: chang ah. Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098. doi: 10.1016/j.bbmt.2019.02.008. Epub 2019 Feb 12. Biol Blood Marrow Transplant. 2019. PMID: 30769193 Free article.
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia.
Pan J, Niu Q, Deng B, Liu S, Wu T, Gao Z, Liu Z, Zhang Y, Qu X, Zhang Y, Liu S, Ling Z, Lin Y, Zhao Y, Song Y, Tan X, Zhang Y, Li Z, Yin Z, Chen B, Yu X, Yan J, Zheng Q, Zhou X, Gao J, Chang AH, Feng X, Tong C. Pan J, et al. Among authors: chang ah. Leukemia. 2019 Dec;33(12):2854-2866. doi: 10.1038/s41375-019-0488-7. Epub 2019 May 20. Leukemia. 2019. PMID: 31110217 Clinical Trial.
Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H, Wei J, Wei G, Luo Y, Shi J, Cui Q, Zhao M, Liang A, Zhang Q, Yang J, Li X, Chen J, Song X, Jing H, Li Y, Hao S, Wu W, Tan Y, Yu J, Zhao Y, Lai X, Yin ETS, Wei Y, Li P, Huang J, Wang T, Blaise D, Xiao L, Chang AH, Nagler A, Mohty M, Huang H, Hu Y. Zhao H, et al. Among authors: chang ah. J Hematol Oncol. 2020 May 4;13(1):42. doi: 10.1186/s13045-020-00873-7. J Hematol Oncol. 2020. PMID: 32366260 Free PMC article. Clinical Trial.
A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia.
Wang Y, Yang Y, Hong R, Zhao H, Wei G, Wu W, Xu H, Cui J, Zhang Y, Chang AH, Hu Y, Huang H. Wang Y, et al. Among authors: chang ah. Blood Cancer J. 2020 Oct 19;10(10):105. doi: 10.1038/s41408-020-00371-6. Blood Cancer J. 2020. PMID: 33077713 Free PMC article. Clinical Trial. No abstract available.
311 results